Stock HAE HAEMATO AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials HAEMATO AG Xetra

Equities

HAE

DE000A289VU3

Pharmaceuticals

End-of-day quote Xetra
Other stock markets
 23:00:00 04/02/2024 GMT 		5-day change 1st Jan Change
26.2 EUR -0.76% Intraday chart for HAEMATO AG -1.50% -5.76%

Valuation

Fiscal Period: December 2023 2024 2025
Capitalization 1 90.96 90.96 -
Enterprise Value (EV) 1 69.66 66.66 62.46
P/E ratio - - -
Yield - - -
Capitalization / Revenue 0.34 x 0.32 x 0.31 x
EV / Revenue 0.26 x 0.24 x 0.21 x
EV / EBITDA 5.34 x 4.63 x 3.83 x
EV / FCF 16.1 x 8.33 x 7.53 x
FCF Yield 6.22% 12% 13.3%
Price to Book - - -
Nbr of stocks (in thousands) 5,228 5,228 -
Reference price 2 17.40 17.40 17.40
Announcement Date - - -
1EUR in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 274.1 197.8 238.3 285 248.1 269.7 281 295.7
EBITDA 1 9.959 - 3.315 12.64 9.661 13.03 14.4 16.3
EBIT 1 - - 1.627 11.16 8.295 11.51 12.86 14.6
Operating Margin - - 0.68% 3.92% 3.34% 4.27% 4.58% 4.94%
Earnings before Tax (EBT) 1 - - - 9.357 10.48 10.23 12.45 14
Net income 1 - - -4.831 6.862 8.193 7.809 9.467 10.41
Net margin - - -2.03% 2.41% 3.3% 2.9% 3.37% 3.52%
EPS - - - - - - - -
Free Cash Flow 1 - - 13.83 13.88 17.12 4.331 8 8.3
FCF margin - - 5.8% 4.87% 6.9% 1.61% 2.85% 2.81%
FCF Conversion (EBITDA) - - 417.11% 109.86% 177.22% 33.23% 55.54% 50.9%
FCF Conversion (Net income) - - - 202.3% 208.98% 55.46% 84.5% 79.73%
Dividend per Share - - - - - - - -
Announcement Date 08/05/19 30/04/20 26/05/21 17/05/22 08/05/23 - - -
1EUR in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2023 Q1
Net sales 1 54.6 66.4 68.4
EBITDA - 2.8 -
EBIT 2 2.4 -
Operating Margin 3.66% 3.61% -
Earnings before Tax (EBT) - - -
Net income - - -
Net margin - - -
EPS - - -
Dividend per Share - - -
Announcement Date 23/05/22 17/08/22 -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - 8.17 - - - - -
Net Cash position 1 - - - 15.2 22.5 21.3 24.3 28.5
Leverage (Debt/EBITDA) - - 2.464 x - - - - -
Free Cash Flow 1 - - 13.8 13.9 17.1 4.33 8 8.3
ROE (net income / shareholders' equity) - - -4.89% 4.84% 5.61% 4.85% 6.1% 6.3%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 1.06 - 0.85 0.29 1.02 0.93 0.9 0.9
Capex / Sales 0.39% - 0.36% 0.1% 0.41% 0.34% 0.32% 0.3%
Announcement Date 08/05/19 30/04/20 26/05/21 17/05/22 08/05/23 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for HAEMATO AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
MERCK KGAA Stock Merck KGaA
+5.48% 71.19B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.55% 9.3B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-13.75% 5.01B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.38% 4.47B
YUHAN CORPORATION Stock Yuhan Corporation
+4.51% 3.96B
INDIVIOR PLC Stock Indivior PLC
+21.10% 2.44B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-19.05% 2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-28.72% 2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.13% 2.02B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HAEK Stock
  4. HAE Stock
  5. Financials HAEMATO AG